David Grieve

David Grieve is a researcher specializing in cardiovascular and respiratory pathophysiology, with a focus on NADPH oxidases, cardiac remodeling, and COVID-19 sequelae. He has led projects funded by the British Heart Foundation investigating reactive oxygen species in endothelial cells and post-infarction cardiac adaptation.

Research Focus: His work bridges molecular cardiology (NADPH oxidase mechanisms, macrophage polarization) and clinical outcomes in COVID-19 (immune aging, dyspnea, sleep disturbances). Recent studies analyze long-term respiratory/cardiac complications in post-hospitalized cohorts.

Publication Trends: Articles (2020–2024) emphasize COVID-19 pathophysiology, while earlier work (2010–2017) explores oxidative stress in cardiac adaptation. Collaborative outputs dominate high-impact journals (The Lancet Respiratory Medicine, PNAS).

Projects:

• Role of NADPH oxidase-derived ROS in cardiac remodelling (BHF, Primary Investigator, 2003–2006)
• Nox4 in endothelial cells in vivo (BHF, Co-Investigator, 2006–2008)

Teams: Active in the PHOSP-COVID consortium, studying multi-organ sequelae in UK-wide cohorts.